Nancy E. Denyes's most recent trade in Atyr Pharma Inc was a trade of 2,687 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 2,687 | 2,687 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 2,687 | 27,454 (0%) | 0% | - | Common Stock | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 03 Feb 2025 | 899 | 26,555 (0%) | 0% | 3.8 | 3,398 | Common Stock |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Purchase of securities on an exchange or from another person at price $ 1.86 per share. | 05 Jun 2024 | 5,000 | 22,267 (0%) | 0% | 1.9 | 9,276 | Common Stock |
| Atyr Pharma Inc | E. Nancy Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 2,688 | 5,374 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | E. Nancy Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 2,688 | 14,767 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | E. Denyes Nancy | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 84,023 | 84,023 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 2,688 | 8,062 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 2,688 | 7,079 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 88,097 | 88,097 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 21,500 | 21,500 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 10,750 | 10,750 | - | - | Restricted Stock Units | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 59,000 | 59,000 | - | - | Employee Stock Option (Right to buy) | |
| Atyr Pharma Inc | Nancy E. Denyes | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) |